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Abstract Several observations have led us to a new hypoth-
esis for cancer mechanism. First, that cancer appears only on
those multicellular organisms with complicated wound-
healing capacities. Second, that wounds considered as risk
factors can be identified in all cancers in clinics. And finally,
thatoncogeneactivationappearsnotonlyincancer,butalsoin
normal physiology and noncancer pathology processes. Our
proposed hypothesis is that cancer is a natural wound healing-
related process, which includes oncogene activations, cyto-
kine secretions, stem cell recruitment differentiation, and tis-
sueremodeling.Woundsactivateoncogenesofsomecellsand
the latter secrete cytokines to recruit stem cells to heal the
wounds. However, if the cause of the wound or if the wound
persists, such as under the persistent UV and carcinogen
exposures, the continuous wound healing process will lead
to a clinical cancer mass. There is no system in nature to stop
orreversethewoundhealingprocessinthemiddlestagewhen
the wound exists. The outcome of the cancer mechanism is
either healing the wound or exhausting the whole system
(death). The logic of this cancer mechanism is consistent with
the rationales of the other physiological metabolisms in the
body—forsurvival.Thishypothesishelpstounderstandmany
cancer mysteries derived from the mutation theory, such as
why cancer only exists in a small proportion of multicellular
organisms,althoughtheyareallunderpotentialmutationrisks
during DNA replications. The hypothesis can be used to
interpret and guide cancer prevention, recurrence, metastasis,
in vitro and in vivo studies, and personalized treatments.
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1 Background: current cancer theories and questions
Given that cancer has not yet been cured, many hypotheses
or theories have been proposed since the beginning of the
last century (Fig. 1). These theories include cancer is caused
by viruses [1], chromosomal abnormalities [2, 3], somatic
mutations [4], accumulated multiple mutations [5], immu-
nological surveillances [6, 7], nonhealing wounds [8], non-
mutagenic mechanisms [9], and tissue organization field
theories [10].
Current prevalent cancer theories hold that cancer is an
uncontrolled somatic cell proliferation caused by the pro-
gressive accumulation of random mutations in critical genes
that control cell growth and differentiation [11–13]. The
immunosurveillance theory plays a supplemental role to
the above mutation theory. When the mutation escapes
immunosurveillance successfully, a clinical tumor will form
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DOI 10.1007/s10555-011-9342-8[7]. However, various paradoxes related to the mutation
theory have been reported previously, such as a slower
proliferation rate of cancer cells than that of normal cells,
silent metastatic tumors, normal tissue formation by inject-
ing teratocarcinoma cells into normal blastocysts, cancer
formation by transplanting normal murine ovary tissue into
the spleen, and spontaneous regression of cancers [10, 14].
In addition, mutation theory cannot explain the following
phenomena:
1. Ifonlyone mutationcausescancer, the chancefor cancers
to form is too great. Mutations require cell divisions.
There are 10
12 stem cell divisions per day in the adult
human body [12]. If the point mutation rate is 1.1×10
−8
per cell division [15] and cancer is caused by one point
mutation [3, 16], then the theoretical cancer occurrence in
everybody would be exceptionally high: 1.1×10
4 point
mutationsorcancersdaily(10
12stemcelldivisions×1.1×
10
−8 point mutation/cell division), meaning everybody
would have the chance of 10,000 cancer cells to form
daily. Thisisobviously not the case. Therefore,a multiple
step mutation cancer theory (mutation–latent–mutation…
to a cancer) [5] and DNA repair theory were developed to
match the actual cancer incidence [12].
Form another perspective, the chance for cancer is too
smallifmultiplespecificmutationscausecancer.Ifcancer
forms from five independent point mutations [11], the
theoretical cancer occurrence would be 10
12×(1.1×
10
−8)
501.61×10
−28 daily per person or 10
12×(1.1×
10
−8)
5×365×12007.05×10
−24fora120-year-oldperson.
It is equivalent to the chance of one cancer case in 1.42×
10
23 people, meaning no one would get cancer in the
world. In clinics, 5∼10 specific genetic alterations, or
even 11,000 genomic alterations per cell were reported
for a sporadic colorectal cancer [17–19], leading to the
question is mutation the cause or the result of a cancer?
Similarly, if the same gene mutation and same expressed
proteins are prevalent in a group of cancer patients (e.g.,
deletions of CDKN2A in bone tumor cell lines [20], p53
and Rb mutations in small cell lung cancer [21]), or in
multiplecancertypes(e.g.,phosphatase and tensinhomo-
log aberrations on various cancers [22]), the chance of
random mutation to cause those cancers simultaneously
should be impossible in theory.
2. Mutation theory does not explain the time difference to
cause cancer in various organisms. More than 50%
Sprague–Dawley rats will develop a spontaneous tumor
in 2 years [23] and this occurrence is far less than one
per million in humans at 2 years old [24]. The doubling
times of bone marrow derived stem cells from humans
and rats are 25.2 h [25] and 31.5 h [26], respectively.
The division rate of human cells is not slower than that
of rat cells, indicating that the chance for DNA replica-
tion mistake in human cells is not any less than that of a
rat’s. From the mutation theory alone, humans have no
reason to show much lower cancer incidence rate than
rats with the same DNA replication time. Similarly,
accumulated mutations cannot explain why the cancer
occurrences are not correlated with the lifespan
among different biological species, e.g., thousands of
year old trees without cancer versus a 12-day-old
Drosophila with cancer, although they have the same
DNA replication mechanisms [27, 28] and similar envi-
ronmental risks that can cause mutations. Furthermore,
from the fact that cancer exists in some multicellular
organisms but not in the others, mutation should not be
the necessary premise of cancer since all multicellular
organisms have potential mutation risks during DNA
replications, while cancer only exists in a small propor-
tion of them.
3. Multicellular organism cells from two different species
in the same potential mutation environment have differ-
ent outcomes on cancerization. Many schistosome-
related human bladder and prostate cancers are reported
[29], while no cancers can be found in the schistosome
itself, although it has the same potential risk of mutation
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248 Cancer Metastasis Rev (2012) 31:247–268from the same cancer environment. If schistosomiasis-
associated bladder cancer is caused by the human p53
mutation [30], why does the same environment never hit
the schistosome’s p53 gene [31] and develop cancer in
the schistosome?
4. Cancer recurrence also cannot be explained by mutation
theory. Supposing one live cancer cell survives after sur-
gical,chemo,andradiationtherapies,anothercancermass
with 1×10
12 cells (about 1 kg) can be formed within
80 days if the cell doubling time is 48 h [32]. If all cancer
cells are killed by the above standard therapies and new
cancer cells are produced by the accumulated mutation
again, according to the mutation theory [11], dozens of
years will be needed to develop like the first one. How-
ever, this does not match the clinical recurrent cases, e.g.,
most breast cancers recur in 5 years [33].
5. Neither mutation theory nor immunosurveillance theory
can explain the cancer incidence rate turnaround at very
old ages in mice (>800 days) [34] and humans
(>85 years) [24, 35, 36]. If mutation and failures of
immunosurveillance or the DNA repair are the causes
of a cancer, the aging cells in very old bodies should
have much more chances of developing cancer. One
explanation to this incidence turnaround is the natural
selection that allows the less cancer-prone population to
survive—the survivors atan old age are not susceptible to
cancer [36]. However, this mechanism, if it exists, con-
flicts with why there is no such phenomenon on other
aging diseases (such as heart disease) [37].
2 Deduction of a new cancer mechanism
There are two possibilities for the relationship between gene
mutation and cancer: first, gene mutation is the cause of a
cancer as mutation theory claims, or second instead of being
the cause, gene mutation is an intermediate process or a result
of a cancerization. Due to many unfit phenomena by the
mutation theory, a better cancer etiology should be considered.
2.1 Wounds as risk factors in cancer
Cancer is accompanied by oncogene activations, which are
also involved in the wound healing process. If a wound is
defined as cellular deaths caused by physical damages (radia-
tion, electromagnetic field, trauma, particles, etc.), chemical
damages(carcinogens,toxicchemicals,heavymetals,etc.)and
biologicaldamages(inflammations, microorganisminfections,
free radicals, nutrient deficiency, aging, stress, etc.), wounds
considered as risk factors are able to be identified in almost all
cancers in clinics. This would include chronic inflammation
andprostatitis to prostatecancer; virus infectionsand trauma to
breast cancer; smoke-induced lesions to lung cancer; chronic
ulcerative colitis to colon cancer; UV damages to skin cancer;
and virus infections, radiation, electromagnetic field to leuke-
mia (Table 1). A study showed that the Rous sarcoma virus
induced tumors only at the wound and inflammation sites
even though the viruses were circulating in the blood, and
the anti-inflammatory agents could inhibit the tumor [38].
Another study even showed that transgenic mice with inflam-
matory genes, LPA and ATX, would have higher incidence of
mastitisfollowedbybreastcancers,whichwasconsistentwith
clinical situations [39, 40]. These broad correlations between
woundsand cancers indicatetwo possibilities:wounds induce
cancer or cancers deal with wounds.
2.2 Oncogenes in wound healing
If oncogenes are defined as the genes that exist in the normal
cells [41] and can transform normal cells into cancer cells
when over-expressed (or tumor suppressor genes in opposite
ways) [42–44], at the molecular level, many oncogenes (if
not all) found in cancers are also found to be active in the
early wound-healing process to proliferate repair cells. The
tumor suppressor genes that are inactivated in cancer are
found to be inactive in the early wound healing and active
again in the late wound healing process to stop the repair
cell proliferation (Table 2). These oncogene activities in the
wound healing indicate that oncogene mechanisms also play
important roles in the wound healing. If cancer is an out-
come of oncogene over-expression, it is possible that a
cancer cell is an assembly of activated oncogenes which
plays a role to help heal the wound. This hypothesis is
supported by the study that the plasma from a tumor-
bearing mouse heals the wound much faster than that from
a normal mouse [45].
2.3 Cancer appearances in multicellular organisms
Expanding to a broader view, most multicellular organisms
on earth are free of cancer, although they all have the same
DNA replication mechanisms (Table 3). From simple to
complicated species, the wound healing process are also
from the simplest (without original wound recovery) to the
intermediate complexities (cell migration, differentiation
and regeneration), to the most complicated wound healing
processes (processes involved in the former plus inflamma-
tion responses, stem cell recruitment, and tissue remodeling,
etc.). Cancer incidences coincide with the complexities of
the wound healing. The more complicated the species, the
more functions and specifically differentiated tissues, the
more complicated the wound healing process. At a certain
level of complexity in wound healing, especially with the
process of inflammation and stem cell recruitment (not
regeneration), the cancer appears in the creatures whether
Cancer Metastasis Rev (2012) 31:247–268 249or not their life spans are longer or shorter. This phenome-
non implies that nature has selected a common mechanism
for wound healing for the complicated species, which is
related to cancer.
All of the above relationships between wound healing and
cancer at evolution, diseases, and molecular levels strongly
indicate one possibility: the wound signaling molecules cause
over-expression of the existing oncogenes (and some other
genes), leading to the changes of certain chromosomes and
cancer cell phenotypes [42], while all the normal cell onco-
gene (not limited to oncogenes) activities responding to
wounds are just a part of the cell’s natural metabolism for
survival. Therefore, a new cancer theory can be logically
speculated: cancer formation is a natural process that organ-
isms have used in wound healing.
2.4 Cancer mechanism on mammals
The following scenario of wound–oncogene–wound healing
(WOWH)isdescribedforthecancermechanismonmammals
(Table 4;L 1 –10). When defined wounds occur in mammals,
the body starts the complicated, inflammatory, and stem cell
involved wound healing (L1). Molecules such as growth
factors, cytokines, and other proteins from the cells in the
wound area interrupt the balance of normal molecular metab-
olism (L2), leading to the activation of corresponding onco-
genes(Table2)andinducingcancerizationinsomecells(stem
cells or actively dividing cells, L3). The cells with activated
oncogenes can secrete molecules to recruit stem cells, stimu-
late stem cell proliferation, and enhance cell differentiation to
repair the wound (L3, L4; Fig. 2A). Oncogenes are activated
in the early stages of the wound and tumor suppressor genes
are activated in the late stages or the healed wound. Mostly,
the wound is healed after above efforts. Oncogenes are deac-
tivated and tumor suppressor genes are activated, then the
metabolism reverts to normal (L5; Fig. 2B). However, if the
wound conditions are still persistent (such as in the situations
ofconstantUVandcarcinogenexposures,andchronicinflam-
mations by microorganisms), this WOWH mechanism will
not stop. Oncogenes will be activated continuously and more
cancer cells (over-activation of the oncogenes transformed
normal cells into malignant cells [43, 44]) are divided to
secrete more molecules for wound healing, forming a clinical
cancer mass (L6; Fig. 2C). After the wound is healed, the
molecules of a healed environment initiate cancer cell differ-
entiation (L7) or apoptosis (L8). Subsequently, the clinical
cancer mass will be gone (Fig. 2D). However, if a small
clinical cancer cannot heal the wound, the cancer mass will
Table 1 Cancers and the wounds considered cancer risk factors in humans
Cancer % of all sites [107] Wound related
Prostate cancer (M) 25% Inflammation [108], chronic prostatitis [109], virus infections [110–112]
Breast cancer (F) 27% Virus infections [113], chronic inflammation [114], electromagnetic field
(EMF) [115], breast trauma [116]
Lung and bronchus 14.5% Chronic inflammation and lesions by smoke [117–119], virus infection [120, 121],
trauma predispose to metastasis [122], particles [123]
Colon and rectum 10% Inflammation [109, 124], Crohn’s disease and chronic ulcerative colitis [125]
Urinary bladder (M) 7% Parasite infection [126], cystitis [125]
Uterine (F) 6% Cervical erosion [127], chronic inflammations [128]
Skin cancer 4.5% UV from the sun [129, 130]
Non-Hodgkin lymphoma 4.5% Hygiene and infections [131], HCV infection [132], mononucleosis [125], EMF [133]
Kidney and renal pelvis 4% Infection [134]; Increased survival on treatments of inflammation [135]
Thyroid (F) 4% Thyroiditis [136, 137]
Leukemia (M) 3% Virus infections [138–141], radiation [142, 143], EMF [133]
Oral cavity and pharynx (M) 3% Gingivitis, lichen planus [125]
Ovary (F) 3% Pelvic inflammatory disease, chronic cervicitis [125, 144]
Pancreas 3% Chronic pancreatitis, hereditary pancreatitis [125]
Brain and nervous system 1.5% Inflammation [145], infections [146], head trauma on meningioma [147], EMF [133]
Liver cancer 1.5% Inflammation [108], sarcoidosis [109], parasite infection [126], alcohol intake [126].
Gall bladder cancer 0.7% Chronic cholecystitis [125]
Gastric cancer 1.4% Gastric ulcers [148], helicobacter pylori infection [149],
Esophageal cancer 1.1% Reflux oesophagitis, Barrett’s esophagus [125]
Hodgkin lymphoma 0.6% EBV infection [150], various infections [151]
The percentages were from the estimated new cases in 2009 from reference [107]. M male, F female, and no indication represent both. The bottom
six cancers were calculated from Table 1 and the others were from Fig. 1 of reference [107]
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Logic Published studies on mammal cells Indication
L1 Human and mouse wound healing involved reepithelialization,
epidermal differentiation, cell migration, proliferation,
inflammatory response as well as dermal closure, matrix
distribution, and skin remodeling [223]
Wound healing in mammal is a complicated procedure
Healing of cutaneous wounds required a complex integrated
network of repair mechanisms, including the action of newly
recruited leukocytes [171]
L2 Many molecules were highly expressed or secreted, and involved
in the process of wound and wound healing, including Bcl-2,
Bcl-XL, fas-fas ligand, TNF-TNF receptor, p53, caspases, etc.
[229]
Many growth factors, cytokines, and other proteins are highly
expressed or secreted during the occurrence of the wound and
wound healing. Those molecules also appear in cancer
T lymphocytes infiltrated wounds and tumors, synthesized and
exported two well-characterized growth factors, heparin-binding
epidermal growth factor-like growth factor (HB-EGF) and basic
fibroblast growth factor (bFGF), mediating fibroblasts and
smooth muscle cells formations in the angiogenesis associated
with wound healing and tumor growth [230]
Cytokines produced by or carried within platelets could be released
at sites of vascular injury and participate in wound healing [231]
Human γδ-T cells secreted connective tissue growth factors during
wound healing [232]
L3 Wound fluids, especially on early time (day 1) promoted tumor
growth on mice [68]
Wound activated oncogenes and induced cancerization
Substance–P, SCF, IL–1 and VEGF were markedly induced after
alkali burn at mouse eye as well as peripheral blood. Substance–p
was the early cytokine induced by alkali burn wound and
stimulated cell proliferation and mobilization of mesenchymal
stem cells [233]
c-Fos- and c-Jun-immunoreactive cells were detected in the epi-
thelial cells and keratocytes around the experimental physical and
chemical cornea injuries on rats [234]
L4 In a murine experimental glioblastoma model, endogenous neural
precursors migrated from the subventricular zone toward the
tumor, surrounded it, and induced glioblastoma cell apoptosis
[235]
Tumor cells recruit stem cells to the tumor sites. Cytokines migrate
and differentiate cells in the wound healing
During wound healing, quiescent corneal keratocytes surrounding
the injured region differentiated into fibroblast or myofibroblast
phenotypes that mediate cell migration, wound contraction, and
matrix remodeling. In a 3D culture model of the corneal stroma,
TGF-β induced the corneal keratocytes to differentiate into
myofibroblasts, and PDGF stimulated significant keratocyte mi-
gration [236]
L5 Fifteen min after the rat cornea epithelial ablation, weak signals for
c-fos and c-jun mRNAs were detected in the corneal epithelium
surrounding the wound. These signals reached a peak 30–60 min
after ablation, but were no longer evident at 120 min [167]
Oncogenes express in the early stage of a wound. Tumor
suppressing genes express in the late stage of a wound. After the
wound healing, those genes are back to homeostasis. Cancer
secretes molecules with the power to heal wounds in the body
p53 expression was decreased to negative in the first 2 days after
wound, increased in 3–5 days and returned to normal after
9 days on the swine skin wound healing process. In contrast, the
oncogene PDGFR expression was negative before wound and
increased 6 h after wound, peak at 1–3 days and returned to
normal 9 days after wound [179]
In the first day after the human skin wound, there was a dramatic
downregulation of p63 expression in wound area. Five days after
the injury, induction of p63 in the basal keratinocytes could be
detected, followed by a gradual increase of its expression in
subsequent days. Several days after complete wound closure, p63
was still strongly expressed not only in the basal keratinocytes
but also in the entire spinous layer, whereas the Ki67 expression
was restricted to single cells in the basal layer [181]
Cancer Metastasis Rev (2012) 31:247–268 253grow large and some part of the cancer itself will be necrotic
(inducing inflammation—a new wound) due to the lack of
nutrients and oxygen (L9). Both the original and new wounds
willinducemorecancerization and leadtoa positivefeedback
loop until the wounds are healed or the whole system is
exhausted (L10; Fig. 2E).
3 Further interpretations of WOWH mechanism
3.1 Dilemma of the cancer mechanism for survival
Allofthe above WOWHprocesses are delicatelyregulatedby
molecular feedbacks among the wounded cells, inflammation
Table 4 (continued)
Logic Published studies on mammal cells Indication
The plasma from tumor-bearing mice healed the wound faster than
the plasma from normal mice [45]
L6 Chronic inflammation and persistent wound healing reactions in
large and small bile ducts often lead to liver cancer [237]
Chronic wounds make oncogenes highly expressed. Oncogenes
transform some cells into cancer cells. Cancer cells secrete
molecules that help to heal wounds The level of both c-fos and c-Ha-ras mRNAs were heavily induced
in the basal layer of epidermis in chronic wounds when compared
to normal skin and acute wounds [238]
c-Ki-ras oncogene was frequently activated in mucous cell
hyperplasias of pancreas suffering from chronic inflammation
[239]
The activated Ras oncogene transformed various mammalian cells
and had been implicated in development of a high population of
malignant human tumors [240]
Platelet-rich plasma obtained from healthy (PRP) or tumor-bearing
(TPRP) mice was applied to dorsal, full-thickness wounds on
diabetic mice. TPRP-treated wounds reached 90% wound closure
5.6–9.5 days earlier than PRP-treated and nontreated wounds,
respectively [45]
L7 After corneal injury, the neurotrophic factor PEDF was increased in
the media at a relative late wound stage (48 h) [241]
Some molecules appeared in the wound healing play a potential
role in promoting differentiation of cancer cells
PEDF blocked angiogenesis and induced differentiation in prostate
cancer [242]
FGF-2 increased after wound closure and inhibited the early
increased TGF-β. TGF-β increased the stromal cell migration for
wound healing [243]
Intracellular FGF-2 significantly inhibited the migratory potential of
T-47D breast cancer cells and promoted those cell differentiations
[244]
L8 PEDF induced endothelial HUVEC apoptosis through the
sequential induction of PPARgamma and p53 overexpression
[245]
Some wound healing molecules induced apoptosis of angiogenesis
and cancer cells
Overexpression of FGF-2 downregulated the oncogene Bcl-2 and
promoted apoptosis in MCF-7 human breast cancer cells [246]
L9 Necrotic cells were characterized by the loss of membrane
integrity, organelle swelling, lysosomal leakage, and inducing a
significant inflammatory response [229]
Necrosis occurs during the cancer mass expansion due to the
nutrient deficiency and hypoxia
Cancer cell expansion, remodeling and regression induced apoptosis
and necrosis due to the nutrient deficiency and hypoxia [247]
Hypoxia induced both apoptosis and necrosis through the
pathways of HIF-1 and NIP3 [248]
L10 Spontaneous regression of cancer was reported in virtually all types
of human cancer [249]
The existence of spontaneous regression of cancer indicates that
cancer, even an advanced one can be a reversible process
Spontaneous regression was reported on multiple sites of
melanoma [250]
A complete clinical spontaneous regression was reported on a lung
cancer with metastases of abdominal wall, liver, and lung [251]
Approximately one half of all cancer patients experienced a
complex metabolic status involving progressive exhaustion of
adipose and skeletal muscle tissue–cachexia [252]
254 Cancer Metastasis Rev (2012) 31:247–268cells, cancer cells, stem cells, extracellular matrix cells, and
healed cells. The more signaling molecules secreted from
wounded and inflamed cells, the more cancer cells respond.
The more signaling molecules secreted from healed wound,
themorecancercellsstopworking(Table4,L 1–10).Different
wounds activate different oncogenes and induce different
cancers to produce different molecules for wound healing.
This WOWH mechanism is developed incredibly well except
for one defect: if wounds persist (such as under chronic
microorganism infections, chronic cervical erosion, etc.), the
cancer mass will grow larger and larger without a natural
mechanism to stop the positive feedback loop in our system
until the whole system becomes exhausted (death). The logic
that normal cells control themselves on developments, wound
healing, and ensuring a homeostasis after the process is un-
derstandable [46]. However, if wound causes and wounds
persist, then what possible mechanisms could nature use to
heal the wound? Continue fighting? Reverse the process?
Facing the persistent wounds, natural selection seems to have
no better choice in logic besides fighting the wounds until the
system becomes exhausted since the chances of the natural
regression of late-stage cancer do exist (Table 4; L10). More
importantly, breaking this positive feedback loop at some
point, e.g., at late stage of a cancer, means all the molecular
responses to the wound must be stopped or reversed, leading
the logical problems for survival—no response or reversal
responses to wounded and aging cells in membranes, skin,
liver, blood cells, and the other fast metabolized tissues. A
study showed the attempts to generate mice that over-express
wild-type p53 gene were unsuccessful on embryo develop-
ment, while the partial p53 activated mice exhibited enhanced
resistance to spontaneous tumors. However, at the same time,
they displayed an early onset of aging in their lives, including
reduced longevity, osteoporosis, generalized organ and tissue
atrophy, retarded wound healing, and less stress tolerance
[47].
3.2 Cancer incidence turnover at very old age
When cancer is considered as a functional repair tissue for
wound, the mystery of cancer incidence turnaround at very
old age can be explained: wound incidence increases along
with age due to the accumulation of injuries, inflammations,
infections, toxins, and cell aging [48]. The wound healing
ability decreases along with age due to cellular aging [49,
50]. Cancer, as a functional wound healing tissue, increases
due to the increased wound incidence along with age, but
decreases due to the exhausted wound healing ability at very
old age (Fig. 3). The lower cancer incidence rate in women
versus men [24] can also be explained by the higher wound
healing ability in women [51].
3.3 Other unexplainable phenomena above
The other unexplainable phenomena by mutation theory
above can be explained by the WOWH mechanism: (1) The
chance to have a clinical cancer is not dependent on gene
mutation numbers, but on the underlying wounds and the
Legends:
Wound causes
A. Oncogene is activated by the 
molecular imbalance of a wound
D.After the wound is 
healed, the cancer cells can 
be redifferenciated or 
apoptotic. Then the clinical 
cancer mass will be gone.
B. Mostly, the wound is 
healed.  Oncogenes  are 
deactivated and metabolism 
goes back to normal.
C. However, if the wound is still persistent, 
more cancer cells are divided rapidly to 
secrete more growth and repair factors for 
wound healing.  Then a clinical cancer forms. 
E. If a small clinical 
cancer can not heal the 
wound, the cancer mass 
will grow big and some 
part will be necrotic due 
to the lack of nutrients 
and oxygen. The 
persistent wounds induce 
more cancerization and 
lead to a positive 
feedback until the wound 
is healed or the whole 
system is exhausted. 
Normal cell
Inflammatory cell
Dead cell
Cancer cell
Signaling molecule
Positive feed back +
Fig. 2 A scheme of the wound–oncogene–wound healing mechanism
Cancer Metastasis Rev (2012) 31:247–268 255wound healing capacity. Multiple wound causing factors will
induce multiple pathways of cancerization to fight the wound.
(2) The time difference of cancer incidence among species is
due to the different cellular aging time among species. The
aging cellular environment is one of the causes of the biolog-
ical wounds in mammals and the WOWH mechanism will be
initiated along with more and more aging cells in the mammal
lifespan instead of the accumulated mutation time. (3) The
reason different creatures have different outcomes on cancer-
ization in the same potential mutation environment is because
they have different wound healing mechanisms. The ones
without the WOWH mechanism will not develop a cancer in
the mutation environment. (4) The cancer recurrence pace
depends on the underlying wounds and the personal wound
healing ability. Persistent wounds (induced from stress [51],
diet [52], air pollution [53], etc.) will speed up the recurrence
pace.
3.4 Healing mechanism other than healing mistake
The commonalities of wound healing and cancer indicate
two possibilities: One is that the process approaches the
wound incorrectly, leading to wounds that do not heal, or
cancer [8, 54]. The other is that nature developed a process
to heal the wound—the WOWH mechanism accompanied
the wound all the time (Fig. 2). The first possibility fits the
situation of the positive feedback loop described above.
However, if the oncogene activations are investigated on a
broader scale, such as in pregnancy [55, 56], embryonic
development [57, 58], menstruation [59], bone and teeth
development [60, 61], as well as wound healing (Table 2),
the commonalities of the those oncogene activities indicate
the molecules with the same functions exist in both normal
and cancer states, rather than a mistake programming de
novo in cancer. Gene mutations were not only in cancer cells
(at a higher rate), but also in benign hyperplasia or precan-
cerous diseases (at a lower rate) [19, 62, 63], indicating that
gene mutations in cancer should be the result of the tissue
adaptations rather than the causes of a cancer. Since cancer
only appears in species with relatively complicated wound
healing, and overall women have about half cancer inciden-
ces less than men [24], this indicates that cancer is not from
a simple random mutation or a programming mistake. On all
of these aspects, the explanations from WOWH mechanism
fit better. The cancer mysteries above and applications be-
low can be understood better and united together only when
cancer is considered as an active wound healing tissue. The
study that plasma from tumor-bearing mice healed the
wound faster than plasma from normal mice [45] is direct
evidence that cancer secretes molecules with the power to
heal wounds in the body.
4 Applications of WOWH mechanism
4.1 Cancer treatment
The capability to distinguish cancer as functional or a mis-
take tissue is very important for cancer treatment strategy. If
cancer is from a mistake in cellular programming, killing
cancer cells is the only choice to treat the disease. However,
if cancer is a part of the wound healing procedure, killing
cancer cells alone may not lead to a cure. A new cancer
mass will grow up after the previous one is removed [64]. A
new signaling pathway will be activated after the previous
one is inhibited [65]. As long as the underlying wound
exists, WOWH mechanism will respond to it until the
wound healing power is exhausted. Furthermore, the mole-
cules in signaling pathways are not singly linked to each
other. Each of them communicates with many other mole-
cules simultaneously in the signaling networks [66]. Block-
ing one or two elements of the networks may delay the
signal flows for a while but cannot block them completely,
as long as wounds exist. In other words, destroying cancer
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256 Cancer Metastasis Rev (2012) 31:247–268cells without healing the underlying wounds will allow for
an eventual recurrence since the cancer mechanism devel-
oped by nature cannot be destroyed in a live mammal. This
may be the reason why survivals of cancer patients with
metastasis have not changed significantly over the past
several decades for the four most common cancers (lung,
breast, prostate, and colon cancers) [67]. Therefore, cancer
treatment strategies should be focused on the treatments of
underlying wound and molecular imbalances after breaking
the positive feedback loop by the current standard therapies
(surgery, chemo and radiation; Fig. 4). The unknown under-
lying wounds and personalized molecular differences make
the approaches of the cancer cure much more difficult than
the traditional standard therapies but it is the only approach
to cure cancer. It depends not only on major drug treatments
but also on other factors that possibly affect wound healing,
such as stress, diet, environment, lifestyle, etc. Cancer cur-
ing is a personalized multidimensional homeostatic process
at molecular level (Fig. 5). By understanding the WOWH
mechanism, the cancer spontaneous regression (Table 4;
L10) can be explained and it can be considered as the
extreme example of cancer cure by correct overall molecular
balances. Treatment with wound fluid at day 10 showed less
transplanted tumor formation in mice than that with wound
f l u i da td a y1[ 68], indicating the possibility that the
molecules from healed wound releases a cancer response
to the wound environment. Speculating from that, it is
possible that molecules derived from the autologous cancer
mass can prevent or treat the recurrence of the original
cancer. This hypothesis is supported by the studies that
chaperone proteins from tumor cells inhibited tumor growth
in several mouse models [69], that second transplanted
tumors inhibited the first one on mice [70] and that epider-
mal growth factor (EGF) cancer vaccine decreased inflam-
mation [71].
4.2 Interpretation of metastasis
Metastasis has been considered as cancer cell migration and
proliferation from the primary site to a distant tissue [72].
However, it is not clear why the metastasis did not occur in
many cancer cell lines in animal models [72–74]. In addition,
how cancer cells pass through the blood–brain barrier on the
lung, breast, and skin cancers remains unclear since it seems
that only cancer cells can pass the barrier but not the smaller
lymphocytes [75]. Based on the WOWH mechanism, another
type of “metastasis without cell migration” is possible: the
corresponding oncogenes on distant sites can be activated by
the persistently circulating wound molecules derived from the
wounds and cancer-related necrosis/inflammations. The cells
Big cancer,
positive
feedback
loop
Cancer 
Wounds
Wound causes
Clinical
Subclinical
Cure of 
Cancer
Emergency 
treatments:
Surgery
Chemo
Radiation
Fig. 4 A scheme of wound, cancer, feedbacks, and treatments. Phys-
ical, chemical, or biological factors cause a wound. A cancer responds
to the wound to heal it. If the wound stimulation is persistent, a positive
feedback loop will be formed till the wound is healed or the whole
body exhausted. Surgery, chemo, and radiation therapies can halt the
positive feedback loop quickly but the treatments themselves are
wound causes. If the wound is persistent, another cancer will reoccur
or be induced. To cure the cancer, all three facets, positive feedback
loop (caner mass), wounds and wound causes must be covered, al-
though the latter two are more complicated and difficult. Plus sign
indicates increasing, promotion or positive feedback. Minus sign indi-
cates decreasing, reduction, or negative feedback
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proliferate, leading to another cancer mass on the remote site
—m a yb ec o n s i d e r e da s“general metastasis” (Fig. 6). For
example, PI3K/AKT pathways are activated in both breast
cancer [76] and bone remodeling [77]. The circulating mole-
cules that activate PI3K/AKT genes of breast cancer cells will
also stimulate those active ones of bone cells, leading to the
over expression of PI3K/AKT and abnormal proliferation of
bonecells—generalmetastasisofbonewithoutcellmigration.
The study ofsecondary tumorinduction [38] is good evidence
to support this hypothesis of general metastasis: The Rous
sarcoma virus induced a wound tumor in chicks, but did not
developmetastasis.However,awoundawayfromtheprimary
tumor developed a tumor at the wound site without primary
tumor cell migration. Even some wound-related molecules
(transforming growth factor beta (TGF-β), acidic fibroblast
growth factor, and basic fibroblast growth factor) could re-
place the actual wound in the second tumor development,
indicating that the molecules similar to the initiation of the
first wound tumor activated the oncogenes of the wound
related cells at the second wound site and developed the
second tumor—general metastasis without a tumor cell mi-
gration. From the concept of general metastasis, it is easier to
understand why it is hard to find the continuous cancer cell
anchorages on the way from the primary site to the distant
metastatic site and how metastatic sites appear in the brain
across blood–brain barrier. As long as wounding molecules
are circulating in the body, according to the WOWH mecha-
nism, they would promote the oncogene activations in the
tissues that have corresponding oncogene activities in their
physiological metabolisms, especially if there is wound heal-
ing process there.
4.3 Tumor marker fluctuations and its uses
Due to oncogene and other cancer-related gene activations in
cancer, many proteins are secreted outside cancer cells and
enter the blood circulation. Serum markers for cancer status
are being tracked by researchers [78, 79] since the serum
samples are easier to be acquired than tissue samples, yet
few markers have proved to be clinically useful so far. Some
predictable markers in one study may fail to be confirmed in
the other study [80, 81]. The difficulty of the clinical use of
biomarkers in cancer is due to the problems of understanding
them. If a marker is considered a unique label of a cancer cell,
no such marker can be found for cancer screening since all
markers in the early stages of cancer can be found in other
noncancer wounded situations [82]( T a b l e2). Based on the
WOWH mechanism, wound, cancer, and wound healing are
interacting.Awoundpromotescancerandthecancerhealsthe
wound (Figs. 2 and 4). Wound, cancer, and wound healing
willshare the mostcommonmolecules.Onlywhen the cancer
enters the positive feedback loop, might the cancer-based
wounds activate some molecular pathways that are rare in
the noncancer status. Therefore, it is hard to find a highly
specific marker in early cancer stage. One the other hand, the
wound, cancer, and wound healing are a dynamic procedure.
Wounds stimulate the expressions of cancer-related markers
(Table 4; L2, L3), while the cancer may decrease those
expressions if the wound status is improved (Table 4;L 7 ,
L8). New wounds, cancer treatments, diet, and life style
[51–53] affect wound–cancer status (Fig. 5) and further
changes the expression of the cancer-related markers, even if
inthelatestageofcancer.Therefore,itisimpossibletousethe
markers fromone cancerstatustopredict the canceroutcomes
in the later stage. That is why there is some discordance of
tissue biomarkers between the primary cancer and the later
metastatic stage [83]. Furthermore, different wounds activate
different oncogenes and induce different cancers to produce
different molecules for wound healing, although these differ-
ent wounds and cancers happen in one organ possibly.
Z=0.5((2X-1)
2-Y
2+1)       or             Z=X
2-Y
2
0   X, Y, Z   1                         -1 X 1; 0 Y 1; -1 Z 1 
Fig. 5 Molecular regulations for the treatments of diseases including
cancer.X-axis:dosesofmajortreatmentmolecules.Theoptimaldosesare
between minimum and max (point B). Y-axis: the influences of all other
possiblemolecularregulationsincancertreatments,fromdrugs,diets,life
styles to psychological influences. Max Y means the best influences. Min
Y means the worst influences. Z-axis: a disease, a cancer mass or cancer-
ization. Min Z means disease free and max means the worst disease
stages. A Disease (cancer)-free point reached by optimal X and max Y.
Only at this situation, the disease (cancer) can be cured. B Partial clinical
response point by optimal X,b u tm i n i m a lY (correct major treatments but
unfortunately with the influences of other wronglife style, etc.). C Partial
clinical response point by maximal Y, but minimal X (wrong major treat-
mentswiththecorrectinfluencesoflifestyles,etc.).Z0X
2−Y
2meansthat
the treatment outcome depends the personalized molecular balances at
multiple dimensions. Cancer-spontaneous regression can be considered
the extreme example to reach the point a in this model
258 Cancer Metastasis Rev (2012) 31:247–268Therefore, one marker change cannot cover all wound–cancer
situations of the cancer that is named by the tissue or organ,
e.g., different expressions of ER±, PR±, and Her-2± in breast
cancer [83].
Based on WOWH mechanism, another cancer-related
marker change may be speculated and used in clinics
(Fig. 7): if each mean±2SD of a cancer-related marker array
from a 20-year-old population is set as the puberty range (the
reference range with less wounds comparing with older peo-
ple), older people would have more and more out-puberty
ranged (OPR, beyond the mean±2SD of 20 years) markers
along with ages since accumulated wounds and aging cells are
increasing along with age [48]. However, the OPR marker
counts in relatively healthy population (Fig. 7, green line) will
Fig. 6 General metastasis.
The corresponding oncogenes
that have activities in their
physiological metabolisms in
the remote tissues can be
activated by persistently circu-
lating wound molecules derived
from the wounds and cancer re-
lated inflammations. The cells
with persistent activated
oncogenes will transform and
over-proliferate, leading to
another cancer mass on the re-
mote site without the primary
cancer cell migration
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Fig. 7 Interactions of cancer-related biomarkers with age, wounds, and
cancer. Each mean±2SD of many cancer-related markers at 20 years old
is set to be the puberty range (the reference range for an adult). Beyond
this, mean±2SD is set to be out-puberty-range (OPR). The normal OPR
marker count baseline from relatively healthy people is increased along
withagedue tothewound accumulations andcellaging(green).Wounds
make higher OPR marker counts above the baseline and a cancer makes
the higher OPR marker counts towards to the baseline after the wound
healing (red line). Point A is the apex of an abnormal marker count peak
and may be a “false positive” point if the pathological and imaging
diagnoses fail to find the cancer. Point B is the correction point after the
wound healing and may be a “false negative or less sensitivity” point if
the pathological and imaging diagnoses find the cancer. Different sam-
pling times for populations lead to false positives or false negatives. By
monitoring dynamic OPR marker counts, the cancerization status can be
seen and personalized treatments can be guided toward the normal
baseline till the cure of cancer
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metastasis (Fig. 7, red line) due to the oncogene activations.
The molecules from wound and wound healing interactions,
including oncogene activations and the cancer cell activities,
will increase the OPR marker counts. When the wound is
healed, the increased OPR marker counts will drop back to
the normal baseline. That is why in the early stage of a cancer,
the markers may or may not be high, e.g., CEA and CA15-3 on
colon and breast cancers, respectively [84]. If the wounds are
intermittent (such as in the situation of UV exposures in the
vacation every year), the OPR marker counts will be up and
down. This may make many “false positive and false negative”
judgments in the clinic or contradictory results in the studies
[85, 86], which is due to the different sampling times of each
individual (Fig. 7, points A, B). If the wound is persistent, or
the cancer enters the positive feedback loop (such as at the late
cancer stage),morewoundingmolecules andrespondinggenes
will be involved [84, 87, 88] and the OPR marker counts will
be maintained at a high level. By monitoring the dynamic OPR
marker counts of a patient and comparing with the normal
baseline, the cancerization status inside the body can be mon-
itoredandthepersonalizedtreatmentscanbeguidedtowardthe
direction of the normal baseline till the cure of cancer.
4.4 Mysteries of transplanted tumor models
It is not easy to transplant cancer cells to form a tumor in a
normal mouse. This has been considered due to the inhibi-
tion of immunity to tumor formation [89]. However, even in
immunodeficient mice, transplanted cancer cells may not
form a tumor efficiently [90, 91]. In some situations, the
transplanted tumor can be only formed in the presence of
functional T lymphocytes [92]. WOWH mechanism gives
another explanation for this phenomenon: there is no correct
wound molecular environment in the normal mouse for
transplanted cancer cells to respond, while nude mice are
partial wounded bodies that some cancer cells with the right
activated genes may respond to them. Due to the partial
wounded bodies, nude mice do not provide molecules that
are suitable for all transplanted cancer cell growth, but the
tumor growth may be promoted by providing a wound
environment [92, 93]. The use of Matrigel (BD Biosciences)
in the transplanted tumor model [94] is an example of such a
situation since TGF-β [38], FGF [38], EGF [95], insulin-
like growth factor-1 [95], platelet-derived growth factor
(PDGF) [96], and nerve growth factor [97] in Matrigel are
all actively expressed factors in wounds and they all can
activate oncogenes, such as Src [98–103], for cancer prog-
ress. The receptor themselves of EGF, FGF, and PDGF are
oncogenes too (Table 2). Since multiple wound-related cyto-
kines are in the Matrigel, one or more of them will match the
pathways that the transplanted cancer cells were previously
activated. Therefore, many unsuccessfully transplanted
human cell lines are easier to grow in mice in the presence
of Matrigel [94] indicating that the host immunodeficiency
or not is not the limiting factor for the tumor formation since
Matrigel is more like an immunostimulator [104–106] rather
than an immunosuppressor. Furthermore, it has been shown
that the wounded body (a) requires fewer transplanted cells
to form a tumor [68] and (b) forms a bigger tumor [92] than
the normal body. It can be speculated that transplanted
tumor cells can even grow in heterogenic and immunocom-
petent mice as long as a corresponding wound existed.
5 Summary
WOWH mechanism is a logic-deduced theory based on the
relationships among cancer, precancerous diseases, onco-
genes, wound healing, and cancer occurrences in all species
of multicellular organisms. Wound triggers the oncogenes to
producecytokinestorecruitanddifferentiatestemcellstoheal
the wound. If the wound is healed, the process will return to
homeostasis. If the wounds are persistent, wounds and the
positivefeedbackmolecules willmakethe cancermassbigger
and bigger until the wounds are healed or the whole system
exhausts. The logic of the WOWH mechanism is consistent
with the rationales of the other physiological metabolisms in
the body—for survival. It helps to understand many cancer
mysteries from the mutation theory. It can be used to interpret
and guide cancer prevention, recurrence, metastasis, in vitro
and in vivo studies, and personalized treatments.
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